-
Communities
-
Explore Vanderbilt communities
By latest
Featured community
Creative Data Solutions (CDS) is a Vanderbilt Shared Resource and has extensive experience in providing effective and robust solutions to challenges pertaining to research data using modern informatics and bioinformatics approaches.
-
- Resources
-
People
-
Publications
-
Explore publications
-
Keyword Connections
Connections to Anti-HIV Agents are shown below. Double-click or tap a node for more information.
Please note that publication matches are limited to 40 in this view. If you expected more, please view all publication matches for Anti-HIV Agents.
Members
- No matching connections
Resources
- No matching connections
Communities
- No matching connections
Publications
- Zambian women's attitudes toward mass nevirapine therapy to prevent perinatal transmission of HIV.
Sinkala M, Stout JP, Vermund SH, Goldenberg RL, Stringer JS
(2001) Lancet 358: 1611-2 - Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1.
Stringer JS, Sinkala M, Goldenberg R, Vermund S, Acosta E
(2003) Lancet 362: 667 - Nevirapine to prevent mother-to-child transmission of HIV-1 among women of unknown serostatus.
Stringer JS, Rouse DJ, Sinkala M, Marseille EA, Vermund SH, Stringer EM, Goldenberg RL
(2003) Lancet 362: 1850-3 - Treatment as prevention for HIV in China.
Vermund SH
(2013) Lancet 382: 1159-61 - HIV prevention in women: next steps.
Vermund SH, Van Damme L
(2011) Science 331: 284 - Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results.
Redwood AJ, Rwandamuriye F, Chopra A, Leary S, Ram R, McDonnell W, Konvinse K, White K, Pavlos R, Koelle DM, Mallal S, Phillips EJ
(2019) J Allergy Clin Immunol 144: 1413-1416.e7 - Betulinic acid derivatives as HIV-1 antivirals.
Aiken C, Chen CH
(2005) Trends Mol Med 11: 31-6 - Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.
Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, d'Arminio Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, M Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N, Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord
(2014) Clin Infect Dis 58: 1312-21 - Rethinking prevention of HIV type 1 infection.
Burns DN, Dieffenbach CW, Vermund SH
(2010) Clin Infect Dis 51: 725-31 - CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).
Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, Monforte AD, Johnson M, Lima VD, Sterling TR, Cavassini M, Wittkop L, Costagliola D, Sterne JAC, Antiretroviral Therapy Cohort Collaboration (ART-CC)
(2017) Clin Infect Dis 65: 959-966 - Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy.
Clough LA, D'Agata E, Raffanti S, Haas DW
(1999) Clin Infect Dis 29: 75-81; discussion 82-4 - A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
Chui CK, Brumme ZL, Brumme CJ, Yip B, Phillips EJ, Montaner JS, Harrigan PR
(2007) Clin Infect Dis 44: 1503-8 - High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.
Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M, Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team
(2008) Clin Infect Dis 46: 1111-8 - Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.
Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP, Adult AIDS Clinical Trials Group Study
(2006) Clin Infect Dis 42: 401-7 - Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group.
Spritzler J, Mildvan D, Russo A, Asthana D, Livnat D, Schock B, Kagan J, Landay A, Haas DW, Adult AIDS Clinical Trials Group
(2003) Clin Infect Dis 37: 551-8 - Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.
Ritchie MD, Haas DW, Motsinger AA, Donahue JP, Erdem H, Raffanti S, Rebeiro P, George AL, Kim RB, Haines JL, Sterling TR
(2006) Clin Infect Dis 43: 779-82 - Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.
Haas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, Hinkle J, Rousseau F, Ingram CD, Shaw A, Lederman MM, Kim RB, Adult AIDS Clinical Trials Group
(2006) Clin Infect Dis 43: 783-6 - Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir.
Thomas M, Hopkins C, Duffy E, Lee D, Loulergue P, Ripamonti D, Ostrov DA, Phillips E
(2017) Clin Infect Dis 64: 1198-1203 - Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?
Phillips EJ
(2006) Clin Infect Dis 43: 103-5 - Oxidant stress is increased during treatment of human immunodeficiency virus infection.
Hulgan T, Morrow J, D'Aquila RT, Raffanti S, Morgan M, Rebeiro P, Haas DW
(2003) Clin Infect Dis 37: 1711-7 - An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy.
Koethe JR, Jenkins CA, Shepherd BE, Stinnette SE, Sterling TR
(2011) Clin Infect Dis 53: 952-60 - Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients.
Weissman SB, Sinclair GI, Green CL, Fissell WH
(1999) Clin Infect Dis 29: 223-4 - Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009.
Hanna DB, Buchacz K, Gebo KA, Hessol NA, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Korthuis PT, Moore RD, Napravnik S, Patel P, Silverberg MJ, Sterling TR, Willig JH, Lau B, Althoff KN, Crane HM, Collier AC, Samji H, Thorne JE, Gill MJ, Klein MB, Martin JN, Rodriguez B, Rourke SB, Gange SJ, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS
(2013) Clin Infect Dis 56: 1174-82 - Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).
May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, D'Arminio Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne JA, Antiretroviral Cohort Collaboration
(2014) Int J Epidemiol 43: 691-702 - Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.
Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, Hicks JK, Wilkinson MR, Haas DW, Kroetz DL, Clinical Pharmacogenetics Implementation Consortium
(2014) Clin Pharmacol Ther 95: 499-500 - The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.
van Heeswijk RP, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, Cameron DW
(2004) Clin Pharmacol Ther 76: 588-97 - Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
Phillips E, Gutiérrez S, Jahnke N, Yip B, Lima VD, Hogg RS, Harrigan PR, Montaner JS
(2007) AIDS 21: 1561-8 - A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.
Benson CA, van der Horst C, Lamarca A, Haas DW, McDonald CK, Steinhart CR, Rublein J, Quinn JB, Mondou E, Rousseau F, FTC-303/350 Writing Group
(2004) AIDS 18: 2269-76 - A review of drug patch testing and implications for HIV clinicians.
Shear NH, Milpied B, Bruynzeel DP, Phillips EJ
(2008) AIDS 22: 999-1007 - Testing and linkage of patients to early care.
Vermund SH
(2011) AIDS 25: 1547-8 - Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine.
Haas DW, Arathoon E, Thompson MA, de Jesus Pedro R, Gallant JE, Uip DE, Currier J, Noriega LM, Lewi DS, Uribe P, Benetucci L, Cahn P, Paar D, White AC, Collier AC, Ramirez-Ronda CH, Harvey C, Chung MO, Mehrotra D, Chodakewitz J, Nguyen BY, Protocol 054/069 Study Teams
(2000) AIDS 14: 1973-8 - Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy.
Kallianpur AR, Hulgan T, Canter JA, Ritchie MD, Haines JL, Robbins GK, Shafer RW, Clifford DB, Haas DW
(2006) AIDS 20: 1503-13 - Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Abgrall S, Ingle SM, May MT, Costagliola D, Mercie P, Cavassini M, Reekie J, Samji H, Gill MJ, Crane HM, Tate J, Sterling TR, Antinori A, Reiss P, Saag MS, Mugavero MJ, Phillips A, Manzardo C, Wasmuth JC, Stephan C, Guest JL, Gomez Sirvent JL, Sterne JA, Antiretroviral Therapy Cohort Collaboration (ART-CC)
(2013) AIDS 27: 803-13 - Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP
(2004) AIDS 18: 2391-400 - An internationally generalizable risk index for mortality after one year of antiretroviral therapy.
Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, Nattermann J, Lampe FC, Bucher HC, Sterling TR, Crane HM, Kitahata MM, May M, Sterne JA
(2013) AIDS 27: 563-72 - Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia.
Stringer JS, Sinkala M, Maclean CC, Levy J, Kankasa C, Degroot A, Stringer EM, Acosta EP, Goldenberg RL, Vermund SH
(2005) AIDS 19: 1309-15 - Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis.
Antiretroviral Therapy Cohort Collaboration (ART-CC), Shepherd BE, Jenkins CA, Parrish DD, Glass TR, Cescon A, Masabeu A, Chene G, de Wolf F, Crane HM, Jarrin I, Gill J, del Amo J, Abgrall S, Khaykin P, Lehmann C, Ingle SM, May MT, Sterne JA, Sterling TR
(2013) AIDS 27: 1321-9 - Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents. Adolescent Medicine HIV/AIDS Research Network.
Douglas SD, Rudy B, Muenz L, Moscicki AB, Wilson CM, Holland C, Crowley-Nowick P, Vermund SH
(1999) AIDS 13: 1629-35 - Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings.
Stringer JS, Sinkala M, Goldenberg RL, Kumwenda R, Acosta EP, Aldrovandi GM, Stout JP, Vermund SH
(2004) AIDS 18: 939-43 - Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.
McIlleron HM, Schomaker M, Ren Y, Sinxadi P, Nuttall JJ, Gous H, Moultrie H, Eley B, Merry C, Smith P, Haas DW, Maartens G
(2013) AIDS 27: 1933-40
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.
